Evidence guide · South Africa

GlyNAC for ageing: what the glycine and NAC trials show

GlyNAC combines glycine and NAC to raise glutathione in older adults. A 24-person trial reported gains in glutathione, gait speed and strength; a trial of 117 people missed its primary endpoint. What the trials and mouse studies show, doses used and NAC safety.

Review type: research summary. This page summarises published research and product labels, cited below.

GlyNAC is a combination of two amino-acid supplements: glycine, and N-acetylcysteine (NAC), a form of the amino acid cysteine. Both are building blocks of glutathione, an antioxidant made inside cells. The combination was developed by a research group at Baylor College of Medicine in Houston, which reported lower glutathione in older adults and studied whether supplying both building blocks could restore it.

Short answer: the human evidence is small. The Baylor group's randomised trial gave GlyNAC to 12 older adults and placebo to 12 for 16 weeks, and reported improvements in glutathione, oxidative stress markers, gait speed and strength. A larger trial, which 114 of 117 people completed, was run by Nestlé researchers with the Profil institute and found that two weeks of GlyNAC did not raise glutathione, its primary endpoint. No trial has shown that GlyNAC slows ageing or extends human life.

The Baylor trials

The first study was a pilot published in 2021. Eight older adults took glycine and NAC for 24 weeks, with no placebo group, and were compared with eight young adults studied once at the start. The authors reported that red blood cell glutathione deficiency and markers of oxidative stress were corrected, and that inflammation, insulin resistance, strength, gait speed, cognition and waist circumference improved. They also reported that the benefits declined after GlyNAC was stopped for 12 weeks. The paper states that none of the authors had conflicts of interest to disclose.

The randomised trial followed, published in the Journals of Gerontology in 2023. Twenty-four older adults aged 61 to 80 with a body mass index above 27 were randomised to GlyNAC or to an alanine placebo for 16 weeks, and 12 young adults took GlyNAC for two weeks. Doses were 100 mg per kilogram of body weight a day each of glycine and NAC, given as capsules filled by a pharmacist. Participants and the study team were blinded. Eleven people completed the GlyNAC arm, 12 the placebo arm and 11 the young adult group. The trial registration lists muscle glutathione concentration as the primary outcome.

  • Glutathione: in the paper's Table 1, muscle glutathione in the GlyNAC group rose from 2.4 to 6.3 mmol/kg muscle over 16 weeks, compared with 7.0 in young adults. The placebo group stayed at 2.4.
  • Gait speed: in Table 2, gait speed in the GlyNAC group rose from 1.13 to 1.34 metres per second (P = 0.032 for the change), and in the placebo group went from 1.11 to 1.16 (P > 0.99). The authors also reported increases in upper and lower body strength, and a trend toward a longer 6-minute walk.
  • Other markers: the authors reported lower plasma oxidative stress markers (TBARS and F2-isoprostanes, each 72% lower), lower markers of inflammation and endothelial dysfunction, lower insulin resistance, lower systolic blood pressure and a smaller waist circumference with GlyNAC, and no improvements with placebo.
  • Safety: creatinine and the liver enzymes ALT and AST did not rise during the trial, and participants did not report any adverse events related to the supplements.

The statistical comparisons in the tables are mostly within each group, before and after supplementation, and against the young adults. With 11 and 12 people per arm, a trial of this size can show that a change is possible, but it cannot show how large or how reliable the effect is in the wider population. The authors describe the volunteers as healthier older adults, and write that future GlyNAC trials with larger numbers of more typical older adults are warranted. The trial was funded by the US National Institute on Aging and a philanthropic gift from the McNair Medical Institute, and the paper declares no conflicts of interest.

The trial that did not confirm it

A second randomised trial, run by Nestlé researchers and the Profil research institute in Neuss, Germany, and published in Frontiers in Aging in 2022, enrolled 117 generally healthy adults aged 60 to 85. They took placebo or GlyNAC at 2.4 g, 4.8 g or 7.2 g a day (equal parts glycine and NAC) for two weeks, and 114 completed the study. At baseline the older adults had higher oxidative stress markers than a young reference group of 20. Total glutathione itself was not lower. The authors report that two weeks of GlyNAC was safe and well tolerated. Total glutathione, the primary endpoint, did not differ from placebo at any of the three doses. The paper defines that endpoint as total glutathione adjusted for haematocrit: 903.5 mg/L per percent haematocrit with placebo and 959.6 with 7.2 g (P = 0.278). The ratio of reduced to oxidised glutathione, reported separately, also did not rise.

In a post hoc analysis of people with above-median malondialdehyde, a marker of oxidative stress, and below-median total glutathione at the start, the 4.8 g and 7.2 g groups pooled showed a 10.47% rise in total glutathione over two weeks (P = 0.016). The authors conclude that GlyNAC "may increase glutathione levels in older adults with high glutathione demand". A post hoc subgroup is a hypothesis, not a confirmed result. The trial was also much shorter than the Baylor study. Several authors are employees of Nestlé, and the paper states that Nestlé Health Sciences holds patents and licences to patents and markets products for the use of glycine and N-acetylcysteine in conditions related to impaired mitochondrial functions.

What the mouse studies show

  • GlyNAC in mice: the Baylor group gave a GlyNAC diet to 16 C57BL/6J mice (8 male, 8 female) from 65 weeks of age, with 16 mice as controls, and reported that the GlyNAC mice lived about 24% longer.
  • Glycine alone: in the National Institute on Aging's Interventions Testing Program, a diet with 8% glycine produced a small (4% to 6%) but statistically significant increase in lifespan in genetically heterogeneous male and female mice. One author reports that a company he is linked to makes and sells a glycine supplement.
  • NAC alone: in an earlier study in the same genetically heterogeneous mice (UM-HET3), only males given NAC lived significantly longer, and the authors say this may have been due to treatment-related inadvertent diet restriction.

Lifespan results in mice are the reason for interest in GlyNAC, not evidence that it extends human life. No published trial has reported human lifespan or an age-related disease outcome.

What is still under way

Baylor is running a randomised trial of glycine plus NAC against an alanine placebo in people with Alzheimer's disease, with cognition, brain glucose uptake and brain inflammation as primary outcomes. ClinicalTrials.gov lists it as active but not recruiting, with an estimated 52 participants and an estimated completion date of 31 December 2027. Until results are published, there is no trial evidence that GlyNAC affects memory or dementia.

NAC is also a medicine

Acetylcysteine, the medicine name for NAC, is given by intravenous infusion for paracetamol overdose, as eye drops for tear deficiency or abnormal mucus, and by mouth to reduce sputum viscosity. The British National Formulary lists asthma and a history of peptic ulceration as cautions for oral use, and uncommon side effects with oral use including nausea, vomiting, diarrhoea, gastrointestinal discomfort, headache, low blood pressure, stomatitis (inflammation of the mouth), tinnitus and fever. Those listings describe acetylcysteine as a medicine. Supplement doses and products differ, and the GlyNAC trials above reported no supplement-related adverse events over 2 to 24 weeks in small groups.

Our view

  • GlyNAC is a plausible idea with thin human evidence: a pilot of eight people, a randomised trial of 24 older adults, and a larger two-week trial that missed its primary endpoint.
  • The positive trials come from the group that developed the combination. In the trial that missed its primary endpoint, several authors are Nestlé employees, and the paper says Nestlé Health Sciences markets products for the use of glycine and N-acetylcysteine in conditions related to impaired mitochondrial functions. A larger, longer trial by a separate group, with clinical outcomes, would settle more than either.
  • The Baylor trial set doses by body weight, at 100 mg per kilogram a day of each. Check the label dose of each ingredient against the trial dose before assuming a product matches the research.
  • The British National Formulary lists asthma and a history of peptic ulceration as cautions for oral acetylcysteine. Anyone with either should speak to a doctor or pharmacist before taking NAC.

South African rules

In South Africa, health supplements are a sub-category of complementary medicines (Category D) regulated by SAHPRA under the Medicines and Related Substances Act 101 of 1965, and SAHPRA publishes guidance on the safety and efficacy of health supplements. SAHPRA's complementary-medicines page says health supplements allow only low-risk indications: general health enhancement without reference to a specific disease, health maintenance, or relief of minor symptoms not related to a disease or disorder. A GlyNAC product sold with a claim to reverse ageing or treat a disease is not supported by the evidence above.

FAQ

Does GlyNAC reverse ageing?

It has not been shown to. The Baylor trial of 24 older adults reported improvements in glutathione and several markers linked to ageing over 16 weeks, but a trial that 114 of 117 people completed found no rise in glutathione after two weeks. No published trial has reported lifespan or an age-related disease outcome in people.

What dose was used in the GlyNAC trials?

The Baylor randomised trial used 100 mg per kilogram of body weight a day each of glycine and NAC for 16 weeks. The Nestlé and Profil trial used 2.4 g, 4.8 g or 7.2 g a day in total, as equal parts glycine and NAC, for two weeks.

Can I take glycine and NAC separately?

The trials used glycine and NAC together. None of those trials compared glycine and NAC taken as separate products with a single combined product. If you take NAC, the British National Formulary's cautions for oral acetylcysteine, asthma and a history of peptic ulceration, are worth raising with a doctor or pharmacist.

Sources

These are the documents this page relies on.

  1. Supplementing Glycine and N-Acetylcysteine (GlyNAC) in Older Adults Improves Glutathione Deficiency, Oxidative Stress, Mitochondrial Dysfunction, Inflammation, Physical Function, and Aging Hallmarks: A Randomized Clinical Trial. J Gerontol A Biol Sci Med Sci. 2023;78(1):75-89Journals of Gerontology: Series A (PubMed 35975308)
  2. GlyNAC randomised clinical trial in older adults: full text (methods, Table 1, Table 2, funding and conflict of interest)PubMed Central (PMC9879756)
  3. Glutathione and Fuel Oxidation in Aging, NCT01870193ClinicalTrials.gov
  4. Glycine and N-acetylcysteine (GlyNAC) supplementation in older adults improves glutathione deficiency, oxidative stress, mitochondrial dysfunction, inflammation, insulin resistance, endothelial dysfunction, genotoxicity, muscle strength, and cognition: Results of a pilot clinical trial. Clin Transl Med. 2021;11(3):e372Clinical and Translational Medicine (PubMed 33783984)
  5. A Randomized Controlled Clinical Trial in Healthy Older Adults to Determine Efficacy of Glycine and N-Acetylcysteine Supplementation on Glutathione Redox Status and Oxidative Damage. Front Aging. 2022;3:852569Frontiers in Aging (PubMed 35821844)
  6. GlyNAC (Glycine and N-Acetylcysteine) Supplementation in Mice Increases Length of Life by Correcting Glutathione Deficiency, Oxidative Stress, Mitochondrial Dysfunction, Abnormalities in Mitophagy and Nutrient Sensing, and Genomic Damage. Nutrients. 2022;14(5):1114Nutrients (PubMed 35268089)
  7. Glycine supplementation extends lifespan of male and female mice. Aging Cell. 2019;18(3):e12953Aging Cell (PubMed 30916479)
  8. Life extension by diet restriction and N-acetyl-L-cysteine in genetically heterogeneous mice. J Gerontol A Biol Sci Med Sci. 2010;65(12):1275-84Journals of Gerontology: Series A (PubMed 20819793)
  9. Glutathione, Brain Metabolism and Inflammation in Alzheimer's Disease, NCT04740580ClinicalTrials.gov
  10. AcetylcysteineBritish National Formulary (NICE)
  11. Complementary medicinesSAHPRA
  12. Complementary medicines: health supplements safety and efficacySAHPRA